⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
SNDX News
Syndax Pharmaceuticals, Inc.
Alamar Biosciences gibt Abschluss der überzeichneten Wandelanleihe-Finanzierung und Erweiterung des Führungsteams bekannt USA - Deutsch USA - Français USA - English APAC - English USA - English USA - čeština
prnewswire.com
AMGN
ILMN
VRTX
RIVN
TROW
PRGS
ALNY
REGN
GILD
BMY
MRK
ABBV
AZN
SNY
NVS
XRAY
EVTC
MYGN
RVTY
VTRS
BIIB
MDLZ
PFE
SNDX
EXAS
CRSP
NTRA
ON
IDXX
MDT
SYK
ISRG
DXCM
COO
AMZN
GOOG
MSFT
NVDA
IBM
INTC
QCOM
AMD
MU
ADBE
CRM
ORCL
SAP
CSCO
ACN
HPQ
DELL
MSCI
FIS
PAYX
ADP
BBBY
ROST
TJX
MCHP
NXPI
SNPS
CDNS
WDC
STX
KLAC
LRCX
AMAT
CTAS
PAYC
NOW
DDOG
ZS
PANW
FTNT
SNOW
PYPL
V
MA
AXP
BAC
JPM
WFC
C
GS
MS
SCHW
ELAN
ZTS
ALGN
XOM
CVX
KO
PEP
MCD
DIS
CMCSA
VZ
T
NFLX
Syndax and World Orphan Drug Alliance to Launch a Multi-Regional Managed Access Program, Expanding Access to Revuforj® (revumenib) Outside the U.S.
globenewswire.com
SNDX
Syndax Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference
globenewswire.com
SNDX
Revuforj® (revumenib) Named Best New Drug at the Scrip Awards 2025
globenewswire.com
SNDX
Syndax Highlights Leadership in Menin Inhibition at ASH 2025 with Multiple Revuforj® (revumenib) Presentations Spanning the Acute Leukemia Treatment Continuum
globenewswire.com
SNDX
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
globenewswire.com
SNDX
Syndax Announces Participation at the 8th Annual Evercore Healthcare Conference
globenewswire.com
SNDX
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
globenewswire.com
SNDX
Syndax Reports Third Quarter 2025 Financial Results and Provides Business Update
globenewswire.com
SNDX
Syndax to Host ASH Investor Event in Person and via Webcast on December 8, 2025
globenewswire.com
SNDX